Posts tagged Bristol-Myers Squibb
WB starts Biohaven at OP

William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26.

Read More
HCW transfers coverage of uniQure at buy

Mark Breidenback of H.C. Wainwright has assumed coverage of uniQure NV (NASDAQ:QURE) with a “buy” rating and $30 price target. The stock closed at $14.89 on Tuesday.

uniQure is developing gene therapies as long-acting, potentially curative treatments for several monogenic, inherited disorders. The company’s core franchise is comprised of a broadly applicable technology platform that produced Europe’s first approved gene therapy, Glybera.

Read More